Marvel Biosciences Corp. (TSXV:MRVL)

Marvel Biosciences Income Statement

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020
Selling, General & Admin	0.87	0.85	1.35	1.13	0.64	0.37
Research & Development	0.34	0.3	0.76	1.38	0.61	0.27
Operating Expenses	1.31	1.22	2.19	2.51	1.25	1.02
Operating Income	-1.31	-1.22	-2.19	-2.51	-1.25	-1.02
Interest Expense	-0.16	-0.11	-0.04	-	-	-
Interest & Investment Income	-	-	-	-	0	0
Currency Exchange Gain (Loss)	-0.12	-0.05	-0	-0	0.01	-0
Other Non Operating Income (Expenses)	-0.07	-0.26	-0.06	-0.04	-0	-0
EBT Excluding Unusual Items	-1.66	-1.65	-2.29	-2.55	-1.24	-1.02
Merger & Restructuring Charges	-	-	-	-	-1.91	-
Other Unusual Items	-	-	-	-	-0.04	-
Pretax Income	-1.66	-1.65	-2.29	-2.55	-3.19	-1.02
Income Tax Expense	-	-	-	-	-0.15	-0.06
Net Income	-1.66	-1.65	-2.29	-2.55	-3.04	-0.96
Net Income to Common	-1.66	-1.65	-2.29	-2.55	-3.04	-0.96
Shares Outstanding (Basic)	42	40	40	33	18	7
Shares Outstanding (Diluted)	42	40	40	33	18	7
Shares Change (YoY)	6.74%	0.77%	21.07%	85.11%	140.11%	-
EPS (Basic)	-0.04	-0.04	-0.06	-0.08	-0.17	-0.13
EPS (Diluted)	-0.04	-0.04	-0.06	-0.08	-0.17	-0.13
Free Cash Flow	-0.99	-1.18	-1.33	-2.19	-1.37	-0.54
Free Cash Flow Per Share	-0.02	-0.03	-0.03	-0.07	-0.08	-0.07
EBITDA	-	-	-2.19	-2.51	-1.25	-1.02
D&A For EBITDA	-	-	0	0	0	0
EBIT	-1.31	-1.22	-2.19	-2.51	-1.25	-1.02

Updated Dec 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.